Skip to Content
Søk Menu

The Choice of Immunotherapy and PARP Inhibitor for Gynecological Cancer

Charlotte Haslund, MD, chief oncologist at the Department of Oncology, Aalborg University Hospital, specializing in gynecological cancer, presented highlights and Danish perspectives on ovarian cancer at the Danish Evening at ESMO 2024.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Hanna Dillekås

Ingen nye studier vil umiddelbart endre brystkreftbehandlingen i Norge, men flere har potensial på sikt

/ Hanna Dillekås
BrystkreftESMO24 Play the Video 01:49

PD-1 Inhibitors Have Shown Remarkable Efficacy

/ BestPractice Nordic
ESMO24Gastrointestinal kreftMage-tarmkreft

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ BestPractice Nordic
ESMO24Gastrointestinal kreftMage-tarmkreft

Several Unsettled Questions About Breast Cancer Treatment

/ BestPractice Nordic
BrystkreftESMO24

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ BestPractice Nordic
ESMO24Gynekologisk kreft

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ BestPractice Nordic
ESMO24Lungekreft
Ingvild Vistad

LETSGO: Trening under gynekologisk kreftbehandling

/ Ingvild Vistad
Gynekologisk kreftOnkologisk Forum 2024 Play the Video 03:11

Ten-Year Survival Data from a Groundbreaking Trial for the Treatment of Metastatic Melanoma

/ BestPractice Nordic
ESMO24Melanom

No Major Breakthroughs in Lung Cancer Compared to ESMO 2023

/ BestPractice Nordic
ESMO24Lungekreft
Back to top